- Datum04.11.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalterstock3 
Madrigal Pharmaceuticals Inc. Chart

Charts analysieren 
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
 Chart analysieren 

Madrigal Pharmaceuticals Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen | 
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK | 
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask | 
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-2,20 %
Intraday
-0,81 %
1 Woche
-6,92 %
1 Monat
35,49 %
Seit Jahresbeginn
61,21 %
1 Jahr
490,34 %
3 Jahre
228,16 %
5 Jahre
Passender Service zu Madrigal Pharmaceuticals Inc.
Webinar zu Madrigal Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)238,043-463,625
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Madrigal Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Madrigal Pharmaceuticals Inc.
- Nov4Madrigal Pharmaceuticals Inc.Q3 2025 Earnings Release
- Mär4Madrigal Pharmaceuticals Inc.Q4 2025 Earnings Release
- Mai12Madrigal Pharmaceuticals Inc.Q1 2026 Earnings Release
Beschreibung
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
